Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism

Journal of Psychiatric Research

Volumn 84, Issue , 2017, Pages 153-160

  Erickson, Craig A ^a   Ray, Balmiki ^b,c   Wink, Logan K ^a   Bayon, Baindu L ^b   Pedapati, Ernest V ^a   Shaffer, Rebecca ^a   Schaefer, Tori L ^a   Lahiri, Debomoy K ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Assurex Health   (United States)

Author keywords

Autistic disorder; Biomarker; Extracellular signal related kinase; Lymphocytes; Neurodevelopmental disorder

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CLONAZEPAM; CLOZAPINE; DEXAMPHETAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANFACINE; LAMOTRIGINE; LITHIUM; MELATONIN; METHYLPHENIDATE; MIRTAZAPINE; MITOGEN ACTIVATED PROTEIN KINASE; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; TRAZODONE; VALPROIC ACID; ZIPRASIDONE; BIOLOGICAL MARKER; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CAUCASIAN; CELL LYSATE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; INTELLECTUAL IMPAIRMENT; MALE; PATHOPHYSIOLOGY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; WESTERN BLOTTING; AUTISTIC DISORDER; BLOOD; CELL COUNT; CYTOSOL; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AUTISTIC DISORDER; BIOMARKERS; BLOTTING, WESTERN; CELL COUNT; CHILD; CHILD, PRESCHOOL; CYTOSOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MALE; MIDDLE AGED; PHOSPHORYLATION; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 84991449237     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.09.003     Document Type: Article

References (60)

1. Adviento, B., Corbin, I.L., Widjaja, F., Desachy, G., Enrique, N., Rosser, T., Risi, S., Marco, E.J., Hendren, R.L., Bearden, C.E., Rauen, K.A., Weiss, L.A., Autism traits in the RASopathies. J. Med. Genet. 51:1 (2014), 10–20.
2. Alley, G.M., Bailey, J.A., Chen, D., Ray, B., Puli, L.K., Tanila, H., Banerjee, P.K., Lahiri, D.K., Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J. Neurosci. Res. 88:1 (2010), 143–154.
3. Bailey, A.R., Giunta, B.N., Obregon, D., Nikolic, W.V., Tian, J., Sanberg, C.D., Sutton, D.T., Tan, J., Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int. J. Clin. Exp. Med. 1:4 (2008), 338–344.
4. Bailey, A.R., Hou, H., Song, M., Obregon, D.F., Portis, S., Barger, S., Shytle, D., Stock, S., Mori, T., Sanberg, P.G., Murphy, T., Tan, J., GFAP expression and social deficits in transgenic mice overexpressing human sAPPalpha. Glia 61:9 (2013), 1556–1569.
5. Balakrishnan, K., Burger, J.A., Fu, M., Doifode, T., Wierda, W.G., Gandhi, V., Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia 16:12 (2014), 1036–1046.
6. Beaulieu, J.M., Sotnikova, T.D., Gainetdinov, R.R., Caron, M.G., Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 281:43 (2006), 32072–32080.
7. Bodles, A.M., Barger, S.W., Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol. Aging 26:1 (2005), 9–16.
8. Branca, M., Ciotti, M., Santini, D., Bonito, L.D., Benedetto, A., Giorgi, C., Paba, P., Favalli, C., Costa, S., Agarossi, A., Alderisio, M., Syrjanen, K., Group, H.P.-P.I.S., Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am. J. Clin. Pathol. 122:6 (2004), 902–911.
9. Busca, R., Christen, R., Lovern, M., Clifford, A.M., Yue, J.X., Goss, G.G., Pouyssegur, J., Lenormand, P., ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1. BMC Evol. Biol., 15, 2015, 179.
10. Campbell, L., Nuttall, R., Griffiths, D., Gumbleton, M., Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer 115:15 (2009), 3457–3467.
11. Caunt, C.J., Keyse, S.M., Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 280:2 (2013), 489–504.
12. Cizmarova, M., Hlinkova, K., Bertok, S., Kotnik, P., Duba, H.C., Bertalan, R., Polockova, K., Kostalova, L., Pribilincova, Z., Hlavata, A., Kovacs, L., Ilencikova, D., New Mutations associated with rasopathies in a central european population and genotype-phenotype correlations. Ann. Hum. Genet. 80:1 (2015), 50–62.
13. Clarke, W.P., Chavera, T.A., Silva, M., Sullivan, L.C., Berg, K.A., Signalling profile differences: paliperidone versus risperidone. Br. J. Pharmacol. 170:3 (2013), 532–545.
14. Cui, Y., Costa, R.M., Murphy, G.G., Elgersma, Y., Zhu, Y., Gutmann, D.H., Parada, L.F., Mody, I., Silva, A.J., Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:3 (2008), 549–560.
15. Curatolo, P., Bombardieri, R., Jozwiak, S., Tuberous sclerosis. Lancet 372:9639 (2008), 657–668.
16. Chévere-Torres, I., Kaphzan, H., Bhattacharya, A., Kang, A., Maki, J.M., Gambello, M.J., Arbiser, J.L., Santini, E., Klann, E., Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the ΔRG mouse model of tuberous sclerosis complex. Neurobiol. Dis. 45:3 (2012 Mar), 1101–1110, 10.1016/j.nbd.2011.12.028 [Epub 2011 Dec 16].
17. Deacon, R.M., Glass, L., Snape, M., Hurley, M.J., Altimiras, F.J., Biekofsky, R.R., Cogram, P., NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med. 17:1 (2015), 71–82.
18. Demars, M.P., Bartholomew, A., Strakova, Z., Lazarov, O., Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin. Stem Cell Res. Ther., 2(4), 2011, 36.
19. Erickson, C., Ray, B., Maloney, B., Wink, L.K., Bowers, K., Schaefer, T.L., McDougle, C., Sokol, D.K., Lahiri, D., Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J. Psychiatri. Res. 59 (2014 Dec), 220–228.
20. Faridar, A., Jones-Davis, D., Rider, E., Li, J., Gobius, I., Morcom, L., Richards, L.J., Sen, S., Sherr, E.H., Mapk/Erk activation in an animal model of social deficits shows a possible link to autism. Mol. Autism, 5, 2014, 57.
21. Fung, L.K., Hardan, A.Y., Autism in DSM-5 under the microscope: implications to patients, families, clinicians, and researchers. Asian J. Psychiatr. 11 (2014), 93–97.
22. Gakhar-Koppole, N., Hundeshagen, P., Mandl, C., Weyer, S.W., Allinquant, B., Muller, U., Ciccolini, F., Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur. J. Neurosci. 28:5 (2008), 871–882.
23. Govindarajan, B., Mizesko, M.C., Miller, M.S., Onda, H., Nunnelley, M., Casper, K., Brat, D., Cohen, C., Arbiser, J.L., Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin. Cancer Res. 9:9 (2003), 3469–3475.
24. Hoey, S.E., Buonocore, F., Cox, C.J., Hammond, V.J., Perkinton, M.S., Williams, R.J., AMPA receptor activation promotes non-amyloidogenic amyloid precursor protein processing and suppresses neuronal amyloid-beta production. PLoS One, 8(10), 2013, e78155.
25. Ishii, D., Matsuzawa, D., Kanahara, N., Matsuda, S., Sutoh, C., Ohtsuka, H., Nakazawa, K., Kohno, M., Hashimoto, K., Iyo, M., Shimizu, E., Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci. Lett. 471:1 (2010), 53–57.
26. Jeste, S.S., Sahin, M., Bolton, P., Ploubidis, G.B., Humphrey, A., Characterization of autism in young children with tuberous sclerosis complex. J. Child. Neurol. 23:5 (2008), 520–525.
27. Kelleher, R.J. 3rd, Govindarajan, A., Jung, H.Y., Kang, H., Tonegawa, S., Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell 116:3 (2004), 467–479.
28. Lahiri, D.K., Sokol, D.K., Erickson, C., Ray, B., Ho, C.Y., Maloney, B., Autism as early neurodevelopmental disorder: evidence for an sAPPalpha-mediated anabolic pathway. Front. Cell Neurosci., 7, 2013, 94.
29. Lefloch, R., Pouyssegur, J., Lenormand, P., Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol. Cell Biol. 28:1 (2008), 511–527.
30. Li, Q., Yang, Z., Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J. Exp. Clin. Cancer Res., 28, 2009, 65.
31. Long, J.M., Ray, B., Lahiri, D.K., MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J. Biol. Chem. 289:8 (2014), 5184–5198.
32. Ma, L., Teruya-Feldstein, J., Bonner, P., Bernardi, R., Franz, D.N., Witte, D., Cordon-Cardo, C., Pandolfi, P.P., Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 67:15 (2007), 7106–7112.
33. Malhotra, D., Sebat, J., CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148:6 (2012), 1223–1241.
34. Maloney, B., Lahiri, D.K., Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurol. 15:7 (2016), 760–774.
35. Mariner, R., Jackson, A.W. 3rd, Levitas, A., Hagerman, R.J., Braden, M., McBogg, P.M., Smith, A.C., Berry, R., Autism, mental retardation, and chromosomal abnormalities. J Autism Dev. Disord. 16:4 (1986 Dec), 425–440.
36. Maski, K.P., Jeste, S.S., Spence, S.J., Common neurological co-morbidities in autism spectrum disorders. Curr. Opin. Pediatr. 23:6 (2011), 609–615.
37. Matsubara, D., Ishikawa, S., Oguni, S., Aburatani, H., Fukayama, M., Niki, T., Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J. Thorac. Oncol. 5:9 (2010), 1317–1324.
38. Merlo, D., Cifelli, P., Cicconi, S., Tancredi, V., Avoli, M., 4-Aminopyridine-induced epileptogenesis depends on activation of mitogen-activated protein kinase ERK. J. Neurochem. 89:3 (2004), 654–659.
39. Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F., Lindemann, L., Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:1 (2012), 49–56.
40. Morgan, J.T., Chana, G., Pardo, C.A., Achim, C., Semendeferi, K., Buckwalter, J., Courchesne, E., Everall, I.P., Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psychiatry 68:4 (2010), 368–376.
41. Naci, D., Aoudjit, F., Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK/Mcl-1 and p38 MAPK pathways. Cell Signal 26:9 (2014), 2008–2015.
42. Osterweil, E.K., Chuang, S.C., Chubykin, A.A., Sidorov, M., Bianchi, R., Wong, R.K., Bear, M.F., Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77:2 (2013), 243–250.
43. Owens, D.M., Keyse, S.M., Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26:22 (2007), 3203–3213.
44. Peng, M., Li, Y., Luo, Z., Liu, C., Laties, A.M., Wen, R., Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Muller cells in vivo. Invest Ophthalmol. Vis. Sci. 39:9 (1998), 1721–1726.
45. Pereira, A., Zhang, B., Malcolm, P., Sugiharto-Winarno, A., Sundram, S., Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor. BMC Neurosci., 15, 2014, 30.
46. Pucilowska, J., Vithayathil, J., Tavares, E.J., Kelly, C., Karlo, J.C., Landreth, G.E., The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. J. Neurosci. 35:7 (2015), 3190–3200.
47. Ray, B., Chopra, N., Long, J.M., Lahiri, D.K., Human primary mixed brain cultures: preparation, differentiation, characterization and application to neuroscience research. Mol. Brain, 7, 2014, 63.
48. Robbins, D.J., Zhen, E., Owaki, H., Vanderbilt, C.A., Ebert, D., Geppert, T.D., Cobb, M.H., Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J. Biol. Chem. 268:7 (1993), 5097–5106.
49. Samuels, I.S., Karlo, J.C., Faruzzi, A.N., Pickering, K., Herrup, K., Sweatt, J.D., Saitta, S.C., Landreth, G.E., Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J. Neurosci. 28:27 (2008), 6983–6995.
50. Samuels, I.S., Saitta, S.C., Landreth, G.E., MAP'ing CNS development and cognition: an ERKsome process. Neuron 61:2 (2009), 160–167.
51. Satoh, Y., Endo, S., Nakata, T., Kobayashi, Y., Yamada, K., Ikeda, T., Takeuchi, A., Hiramoto, T., Watanabe, Y., Kazama, T., ERK2 contributes to the control of social behaviors in mice. J. Neurosci. 31:33 (2011), 11953–11967.
52. Sokol, D.K., Chen, D., Farlow, M.R., Dunn, D.W., Maloney, B., Zimmer, J.A., Lahiri, D.K., High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J. Child. Neurol. 21:6 (2006), 444–449.
53. Sokol, D.K., Maloney, B., Long, J.M., Ray, B., Lahiri, D.K., Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76:15 (2011), 1344–1352.
54. Tetreault, N.A., Hakeem, A.Y., Jiang, S., Williams, B.A., Allman, E., Wold, B.J., Allman, J.M., Microglia in the cerebral cortex in autism. J. Autism Dev. Disord. 42:12 (2012 Dec), 2569–2584, 10.1007/s10803-012-1513-0.
55. Tian, D., Stoppel, L.J., Heynen, A.J., Lindemann, L., Jaeschke, G., Mills, A.A., Bear, M.F., Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion. Nat. Neurosci. 18:2 (2015), 182–184.
56. Uzan, B., Poglio, S., Gerby, B., Wu, C.L., Gross, J., Armstrong, F., Calvo, J., Cahu, X., Deswarte, C., Dumont, F., Passaro, D., Besnard-Guerin, C., Leblanc, T., Baruchel, A., Landman-Parker, J., Ballerini, P., Baud, V., Ghysdael, J., Baleydier, F., Porteu, F., Pflumio, F., Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression. EMBO Mol. Med. 6:6 (2014), 821–834.
57. Wang, X., Snape, M., Klann, E., Stone, J.G., Singh, A., Petersen, R.B., Castellani, R.J., Casadesus, G., Smith, M.A., Zhu, X., Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J. Neurochem. 121:4 (2012), 672–679.
58. Yamagata, Y., Kaneko, K., Kase, D., Ishihara, H., Nairn, A.C., Obata, K., Imoto, K., Regulation of ERK1/2 mitogen-activated protein kinase by NMDA-receptor-induced seizure activity in cortical slices. Brain Res. 1507 (2013), 1–10.
59. Yufune, S., Satoh, Y., Takamatsu, I., Ohta, H., Kobayashi, Y., Takaenoki, Y., Pages, G., Pouyssegur, J., Endo, S., Kazama, T., Transient blockade of ERK phosphorylation in the critical period causes autistic phenotypes as an adult in mice. Sci. Rep., 5, 2015, 10252.
60. Zhang, Z., Zhou, X., Shen, H., Wang, D., Wang, Y., Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med., 7, 2009, 41.